In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

WuXi PharmaTech completes $156mm IPO on NYSE

Executive Summary

Chinese CRO WuXi PharmaTech has netted $155.9mm in its IPO on the NYSE by selling about 12mm American Depository Shares--including the overallotment--at $14 apiece (above its proposed $11-13 range); selling shareholders issued an additional 3.2mm ADSs.
Deal Industry
  • Biotechnology
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies